Table 1.
Author/Year | Treatment | Phase | Advanced Malignancy | ORR (CR + PR)a | SDb |
---|---|---|---|---|---|
Atzori et al, 2011 (25) | Dalotuzumab | I | Solid tumors | 0% | 8% |
Reidy-Lagunes, 2012 | Dalotuzumab | I | Neuroendocrine tumors | 0% | NR |
Brana, 2014 | Dalotuzumab + MK-2206, ridaforolimus, or MK-0752 | I | Solid tumors | 0%/0%/0% | 37%/50%/0% |
Doi, 2013 | Dalotuzumab + cetuximab and irinotecan | I | Colorectal | 15% | NR |
Ellis, 2014 | Dalotuzumab + cisplatin and etoposide | I | SCLC | 67% | 17% |
Di Cosimo et al, 2015 (26) | Dalotuzumab + ridaforolimus | I | Solid tumors | 7% | 46% |
Moran et al, 2014 (32) | Dalotuzumab + erlotinib | I/II | NSCLC | 3% | 57% |
Olmos et al, 2010 (19) | Figitumumab | I | Sarcoma | 7% | 29% |
Haluska et al, 2007 (17) | Figitumumab | I | Solid tumors | 0% | 67% |
Haluska et al, 2010 (18) | Figitumumab | I | Adrenocortical carcinoma | 0% | 57% |
Juergens, 2011 | Figitumumab | I/II | Ewing sarcoma | 14% | 24% |
Chi, 2012 | Figitumumab | II | Prostate | 94%c | NR |
Becerra, 2014 | Figitumumab | II | Colorectal | 0% | NR |
Schmitz, 2012 | Figitumumab | II | HNSCC | 0% | 12% |
Goto, 2012 | Figitumumab + carboplatin and paclitaxel | I | NSCLC | 39% | 44% |
Karp et al, 2009 (20) | Figitumumab + carboplatin and paclitaxel | I | Solid tumors | 36% | 38% |
Karp et al, 2009 (21)d | Figitumumab + carboplatin and paclitaxel | II | NSCLC | 54% | NR |
Langer et al, 2014 (31) | Figitumumab + carboplatin and paclitaxel | III | Nonadeno-NSCLC | 33% | 37% |
Lacy et al, 2008 (16) | Figitumumab + dexamethasone | I | Multiple myeloma | 33% | 48% |
Molife and colleagues, 2010 (19) | Figitumumab + docetaxel | I | Solid tumors | 10% | 31% |
de Bono, 2014 | Figitumumab + docetaxel and prednisone | II | Prostate | 52%e | NR |
Scagliotti et al, 2015 (33) | Figitumumab + erlotinib | III | Nonadeno-NSCLC | 5% | 39% |
Quek, 2011 | Figitumumab + everolimus | I | Sarcoma and solid tumors | 6% | 83% |
Murakami, 2012 | Ganitumab | I | Solid tumors | 0% | 37% |
Strosberg, 2013 | Ganitumab | II | Carcinoid and pancreas | 0% | 34% |
Tap et al, 2012 (24) | Ganitumab | II | Ewing and desmoplastic | 6% | 49% |
Robertson, 2013 | Ganitumab + exemestane or fulvestrant | II | Breast cancer | 8% | 35% |
Cohn, 2013 | Ganitumab + FOLFIRI | II | Colorectal | 8% | 59% |
Kindler, 2012 | Ganitumab + gemcitabine | II | Pancreas | 10% | 51% |
Okusaka, 2014 | Ganitumab + gemcitabine | I | Pancreas | 0% | 80% |
Van Cutsem, 2014 | Ganitumab + panitumumab | I/II | Colorectal | 22% | 61% |
Rosen, 2012 | Ganitumab + sorafenib, panitumumab, erlotinib, or gemcitabine | I | Solid tumors | 9% | 66% |
Puzanov et al, 2015 (29) | Linsitinib | I | Solid tumors | 1% | 36% |
Jones et al, 2015 (30) | Linsitinib | I | Solid tumors | 3% | 41% |
Fassnacht et al, 2015 (35) | Linsitinib | III | Adrenocortical carcinoma | 3% | 32% |
Bendell and colleagues, 2015 (26) | Linsitinib + everolimus | I | Colorectal | 0% | NR |
Mahadevan, 2014 | R1507 | I | Solid tumors | 36% | 40% |
Abbreviations: CR, complete response; HNSCC, head and neck squamous cell carcinoma; NR, not reported; ORR, overall response rate; PR, partial response; SCLC, small-cell lung cancer; SD, stable disease. Data are from clinical trials investigating the efficacy of inhibition of the IGF1R in the treatment of various types of advanced malignancy.
CR and PR were determined by Response Evaluation Criteria In Solid Tumors criteria.
Duration of SD varied by study.
Partial response was measured by a greater than or +25% decrease in serum prostate-specific antigen.
Partial response was measured by decrease in prostate-specific antigen.
Study was retracted in 2012.